2025-05-27
A SENOVA fará uma exposição na
Tempo: 2024-09-06
Fonte: SenovaTech
Autor: SENOVA—Lucas
Tirzepatide Costs
Mounjaro 5 mg/0.5 mL subcutaneous injection: $1,135 per month supply
Zepbound 5 mg/0.5 mL subcutaneous injection: $1,125 per month supply
Semaglutide Costs
Ozempic 2 mg/3 mL subcutaneous injection: $1,029 per month supply
Wegovy 2.4 mg/3 mL subcutaneous injection: $1,430 per month supply
Rybelsus 7 mg oral tablet: $1,029 for a 30-day supply of 30 tablets
The Cost-to-Outcome (CNT) is calculated by multiplying the drug cost (from common U.S. drug discount websites) by the follow-up time and then dividing it by the average percentage weight loss compared to placebo for each drug.
The results show that tirzepatide leads to a 17.8% weight loss, while semaglutide results in 12.4%.
The total cost of tirzepatide treatment for 72 weeks is estimated at approximately $17,500, while 68 weeks of semaglutide treatment costs $22,800.
Overall, the cost per 1% weight loss for tirzepatide is $985, while for semaglutide it is $1,845.
Which Should I Choose - Tirzepatide or Semaglutide?
In the category of glucagon-like peptide-1 (GLP-1) receptor agonists, factors such as the risk of severe heart disease, history of heart disease (previous heart attack or stroke), A1C levels, weight loss needs, cost and insurance coverage, and patient preferences are important considerations when determining which medication to use.
You and your healthcare provider should consider your personal needs when choosing a treatment for type 2 diabetes or weight loss. What works best for others may not be the best choice for you. You might consider:
Cardiovascular Risk Factors: Semaglutide (Ozempic and Wegovy) has been shown to reduce cardiovascular risks in patients with heart disease, such as heart attacks, strokes, and heart-related deaths. Cardiovascular outcome studies for tirzepatide are still ongoing.
Side Effects: Studies indicate that tirzepatide may have a greater impact on weight loss and A1C levels, but higher doses of tirzepatide are also associated with more severe gastrointestinal side effects, such as nausea, vomiting, and diarrhea.
Formulations: Most of these products are available as injectables. If you prefer not to use injectables for treating type 2 diabetes, Rybelsus is an oral form of semaglutide taken once daily.
Use in Children: All semaglutide and tirzepatide products are approved for adults. Currently, only Wegovy is approved for weight loss in children aged 12 and older.
Affordability: Cash costs and insurance coverage are important considerations. Many insurers do not cover the costs of these drugs, especially for weight loss. Consult your insurance before deciding on treatment with your healthcare provider. There may be more affordable options.
